What are the main functions and effects of ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib (Ibrutinib) is an oral small molecule BTK inhibitor, mainly used to treat various types of hematological malignancies, especially non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia. Its main mechanism of action is to inhibit the growth and survival of tumor cells by selectively inhibiting the activity of Bruton's tyrosine kinase (BTK) and blocking the B cell receptor signaling pathway.

BTK is a key tyrosine kinase widely involved in the development, survival and function of B cells. By inhibiting BTK, ibrutinib can significantly reduce B cell receptor signaling and interfere with cancer cell proliferation and survival. In addition, BTK is also involved in the immune evasion mechanism in the tumor microenvironment. Through its action, ibrutinib can also affect the tumor microenvironment, thereby enhancing the immune system's elimination of tumors.

Clinical studies have shown that ibrutinib has significant effects on mostB cell tumor types, especially in the treatment of certain refractory and relapsed lymphomas. Patients generally experience longer progression-free survival with ibrutinib, making it an important disease control option for many patients. For patients with chronic lymphocytic leukemia, ibrutinib can not only slow down the progression of the disease, but also significantly improve the patient's quality of life and reduce the incidence of disease-related complications.

In general, the main effect of ibrutinib/ibrutinib is that it inhibits BTK, blocks the signaling of malignant B cells, and improves the prognosis of patients with various hematological malignancies, making it an important drug for the treatment of these diseases.

Reference materials:https://www.imbruvica.com/